AAB 003

Drug Profile

AAB 003

Alternative Names: AAB-003; PF-05236812; PF-5236812

Latest Information Update: 12 Mar 2015

Price : $50

At a glance

  • Originator Elan Corporation; Wyeth
  • Developer JANSSEN Alzheimer Immunotherapy; Pfizer
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 06 Nov 2014 Discontinued - Phase-I for Alzheimer's disease in USA and South Korea (IV)
  • 31 Aug 2014 Pfizer & JANSSEN Alzheimer Immunotherapy complete a phase I trial for Alzheimer's disease in USA & South Korea (NCT01369225)
  • 12 Dec 2013 Pfizer & JANSSEN Alzheimer Immunotherapy suspend enrolment in a phase I extension trial for Alzheimer's disease in USA and South Korea (NCT01369225)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top